Evekeo vs Adderall: No Clinically Meaningful Therapeutic Difference
Both Evekeo (racemic amphetamine sulfate) and Adderall (mixed amphetamine salts) are essentially equivalent in therapeutic efficacy for ADHD treatment, with no evidence demonstrating superiority of one over the other in terms of morbidity, mortality, or quality of life outcomes.
Key Compositional Differences
The primary distinction lies in their formulation:
- Evekeo: Contains a 1:1 ratio of d-amphetamine to l-amphetamine (racemic mixture) 1
- Adderall: Contains mixed amphetamine salts with a 3:1 ratio favoring d-amphetamine (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate) 2
Therapeutic Equivalence
Both medications work through identical mechanisms—reuptake inhibition and release of dopamine and norepinephrine—and belong to the same class of first-line ADHD stimulant treatments 3. The evidence shows:
Efficacy: Evekeo demonstrated significant improvement in ADHD symptoms with effect onset at 45 minutes extending through 10 hours postdose 1. Adderall showed a 42% decrease in ADHD Rating Scale scores with 70% of patients achieving clinically meaningful improvement 4
Effect sizes: Both achieve large effect sizes for reducing ADHD core symptoms, consistent with all amphetamine-based stimulants 3
Duration of action: Both immediate-release formulations provide 3-4 hours of symptom control 5
Practical Clinical Considerations
When choosing between these medications, focus on:
- Availability and cost: Generic availability and insurance coverage often drive the decision in real-world practice
- Individual response: Some patients may respond better to one formulation over another due to the different d-/l-amphetamine ratios, though this is unpredictable and requires trial-and-error
- Side effect profile: Both share identical adverse effects (decreased appetite, sleep disturbances, increased blood pressure/pulse, headaches) 3, 2, 1
Common Pitfalls to Avoid
Do not assume the different ratios translate to clinically superior outcomes. The theoretical pharmacological differences in d-/l-amphetamine ratios have not been demonstrated to produce meaningful differences in ADHD symptom control, functional outcomes, or quality of life in head-to-head comparisons.
Monitor identically for both medications: cardiovascular parameters (blood pressure, pulse), growth parameters (height, weight), psychiatric symptoms, and abuse potential 2. Both are Schedule II controlled substances with equivalent abuse liability.
Bottom Line Algorithm
- Start with whichever is more accessible/affordable for your patient
- Titrate to optimal dose based on symptom response (typically 0.14-0.54 mg/kg/day) 6, 4
- If inadequate response after proper titration, switch to the alternative amphetamine formulation or consider methylphenidate 3
- If both fail, move to lisdexamfetamine before considering non-stimulants 3
The choice between Evekeo and Adderall should be driven by practical factors (cost, availability, insurance coverage) rather than expectations of therapeutic superiority, as current evidence does not support meaningful clinical differences between these two amphetamine formulations.